Minneapolis, February 5 /PRNewswire/ --

- Designed for High Security, Reliable Connectivity and Cost Efficiencies.

Multi-Tech(R) Systems, Inc., a leading data communications and telecommunications technology manufacturer based in Minneapolis, Minnesota, and Symstream(TM) Technology Group Ltd., an Australian-based wireless technology company, announced today an alliance to deliver a wireless modem solution that enables wireless transaction services utilizing the GSM/3g networks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040505/MTSLOGO)

LONDON, February 4 /PRNewswire/ --

- Long-time director Andrew Reicher takes over as CEO

Globeleq Generation Limited, the developer of new power generation focused solely on the emerging markets of Africa, the Americas and Asia, announced today the appointment of a new Chief Executive Officer and a new Chairman of its Board of Directors.

Torbjorn Caesar, CEO of the Globeleq business since June 2006, was named Chairman of the Board of Directors and Andrew Reicher, a director of the Globeleq business since 2004, was named as CEO. Both appointments are effective immediately.

CERRITOS, California, February 4 /PRNewswire/ --

Calnetix Inc., a global leader in high efficiency electric motors and generators, today announced the promotion of Brad Garner to President & CEO.

Mr. Garner was hired as Chief Operating Officer (COO) of Calnetix in March of 2007. Since then, Mr. Garner has made a substantial contribution to the business and, as anticipated at the time of his hire, was promoted by the Board of Directors to the President & CEO role. Concurrent with this promotion Mr. Garner was also appointed a position on the Board as Director of Calnetix.

GENEVA, February 4 /PRNewswire/ -- Acrongenomics, Inc. (OTC: AGNM) is pleased to announce that they have acquired a 10.9% interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its technology.

GAITHERSBURG, Maryland, February 4 /PRNewswire/ --

MedImmune announced today it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab BLA is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients were evaluated.